Business
Exclusive distribution agreement
Exclusive distribution agreement.
About this update from Optibiotix Health Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 1465B\n OptiBiotix Health PLC\n 06 October 2020\n \n \n \n OptiBiotix Health plc\n (\"OptiBiotix\" or the \"Company\")\n \n Exclusive distribution agreement with United Italian Trading Corporation (Pte) Ltd\n Exclusive rights to CholBiomeX3 in Singapore\n \n \n OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare, announces that its wholly-owned subsidiary, ProBiotix Health Ltd (\"ProBiotix\"), has entered into an exclusive distribution agreement with United Italian Trading Corporation (Pte) Ltd (\"UITC\") to distribute OptiBiotix's cholesterol reducing product, CholBiomeX3, in Singapore.\n \n \n \n UITC (https://uitc.com.sg) is an established pharmaceutical and medical device marketing and distribution company founded in Singapore in 1963. UITC distributes pharmaceutical and medical products to a wide variety of clients that include hospitals, polyclinics, medical specialists clinics, family physician clinics, and pharmacies. As an established marketing distribution agency, UITC delivers complete and integrated marketing and distribution services in the healthcare sector. Their core strength is their ability to introduce proven innovative products into the market by working with key opinion leaders, organising user experience clinical trials and selling into major hospitals and clinics.\n \n \n \n UITC has agreed to place an order for 5,000 boxes of CholBiomeX3 for delivery by the end of 2020 and increasing annual minimum order quantities to retain exclusivity.\n \n \n \n \n This agreement is another example of the increasing number of pharmaceutical companies commercialising CholBiome® products into the high value GP, hospital and pharmacy markets.\n \n \n \n \n Mikkel Hvid-Hansen, Commercial Director of ProBiotix Health\n commented: \"We are pleased to have signed an agreement with UITC to distribute CholBiomeX3 in Singapore. This follows on from a recent agreement (RNS: 28 September 2020) we signed with UITC for SlimBiome Medical. LPLDL® containing products, like CholBiomeX3, which have peer-reviewed scientific publications and clinical studies are increasingly attracting the interest of pharmaceutical companies who commercialise products in the high value hospit...